Philip R. Clingan
University of Wollongong(AU)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Cancer Treatment and Pharmacology
Most-Cited Works
- → Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer(2018)6,458 cited
- → Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer(2004)3,623 cited
- → Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial(2009)2,274 cited
- → Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer(2020)1,132 cited
- → Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study(2015)941 cited
- → Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial